Multiparametric [18F]F-AraG Imaging for Long COVID (PASC)
This study is looking at how a special imaging technique, called total-body PET/CT, can help us understand Long COVID (PASC). Researchers will use a tracer called [¹⁸F]F-AraG, which helps them see immune cell activity in the body. You would receive an injection of [¹⁸F]F-AraG, followed by PET/CT scans and blood tests. The goal is to find out where immune cells are active in people with Long COVID, how this activity relates to their symptoms, and how it changes over time. This information could help develop better ways to assess and manage Long COVID in the future. The study is currently recruiting and aims to enroll 51 participants.
- Study design
- This is an open-label research study, meaning you and the researchers will know what intervention you are receiving. It is not randomized. The study plans to enroll 51 participants, including people with Long COVID and those who have recovered from COVID-19.
- What's involved
- You would have PET/CT scans, blood draws (up to 42 mL total per visit), and complete symptom questionnaires. Some participants will have follow-up scans at 4 and 8 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- A subset of participants with Long COVID will be followed for 8 months, with scans at baseline, 4 months, and 8 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
At a glance
Conditions
NCT07076862
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
UC Davis EXPLORER Molecular Imaging Center
Sacramento, Californiastudy coordinator listed
Recruiting
University of California San Francisco
San Francisco, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Negar Omidvari, PhD · PRINCIPAL_INVESTIGATOR · University of California, Davis
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Quantification of [¹⁸F]F-AraG uptake kinetics in PASC and control participantsBaseline Imaging Visit
To assess immune activation in convalescent COVID-19, dynamic PET/CT scans will be analyzed to generate time-activity curves (TACs) in multiple tissues. Kinetic modeling will be applied to extract uptake parameters including SUV, SUVR, Vt, Ki, and k3. These values will be reported and statistically compared between PASC and control participants.
- Correlation between [¹⁸F]F-AraG uptake parameters and blood-based markers of immune dysregulationBaseline imaging visit and baseline blood draw
Spearman correlation tests and heat map clustering will be used to assess the association between PET-derived uptake measures and plasma biomarkers of inflammation and immune activation. Correlations will be examined in tissues showing significant uptake differences between study groups.
- Longitudinal change in [¹⁸F]F-AraG uptake and correlation with PASC symptom scoresBaseline, 4-month, and 8-month follow-up visits (subset of PASC participants only)
In a subset of participants, follow-up PET/CT imaging at 4 and 8 months will be used to assess within-subject change in kinetic uptake parameters. These changes will be compared to changes in symptom burden as measured by PHQ-15 symptom domain scores.